Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

May

Today In Oncology

Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma

Effects of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters in Prostate Cancer Survivors

Hemihepatectomy Outcomes With Laparoscopic vs Open Surgery

T-DXd vs Physicians Choice of Therapy in HER2-Positive Metastatic Breast Cancer PROs in DESTINY-Breast02

Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos